Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 285 publications.

La E, Bunniran S, Garbinsky D, Reynolds M, Poston S, Harrington L. Respiratory syncytial virus (RSV) knowledge, attitudes, and perceptions among adults with chronic pulmonary conditions in the US. Poster presented at the ATS American Thoracic Society 2023; May 19, 2023. Washington, DC.

Verelst F, La E, Graham J, Molnar D. Leveraging time-use data to estimate market and non-market productivity losses due to respiratory syncytial virus (RSV) disease among adults aged ≥60 years in the United States (US). Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA.

Molnar D, La E, Verelst F, Curran D, Poston S, Van Bellinghen LA, Graham J. Assessing the public health impact of the adjuvanted respiratory syncytial virus prefusion F protein vaccine among older adults in the United States (US). Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA.

Khan AH, Kosa K, De Prado Gomez L, Whalley D, Kamat S, Clark M. Content validation of patient-reported sleep measures and development of a conceptual model of sleep disturbance in patients with moderate-to-severe, uncontrolled asthma. Patient Relat Outcome Meas. 2023 Mar 23;14:57-71. doi: 10.2147/PROM.S392666

Molnar D, La E, Verelst F, Curran D, Poston S, Graham J. Modeling the clinical and economic burden of respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Talbird S, Cook C, DeMartino J, Hernandez-Pastor L, Krishnarajah G. Projected impact of RSV vaccine in US adults ≥ 60 years of age. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Colosia A, Costello J, McQuarrie K, Kato K, Bertzos K. Systematic literature review of the signs and symptoms of respiratory syncytial virus. Influenza Other Respi Viruses. 2023 Feb 5;17(2):e13100. doi: 10.1111/irv.13100

Herring W, Shen Q, Zhang Y, Martin A, Otiker T, Zhang W. The relationship between Asthma Control Questionnaire scores and exacerbation risk, resource utilization, and utility values: an analysis from the CAPTAIN trial. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S36. doi: 10.1016/j.jval.2022.09.174

Bali V, Schelfhout J, Sher M, Peters A, Patel G, Mayorga M, (DeMuro) Romano C. Patient-reported symptoms, impacts, and treatment preferences in refractory or unexplained chronic cough: a qualitative study. Poster presented at the 2022 Advancing Allergy & Immunology Care (ACAAI) Annual Scientific Meeting; November 13, 2022. Louisville, KY.

La E, Bunniran S, Garbinsky D, Reynolds M, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among older adults in the United States. Poster presented at the 12th International RSV Symposium; September 29, 2022. Belfast, Ireland.

Costello J, Colosia A, Bertzos K, McQuarrie K. Systematic literature review of the signs and symptoms of respiratory syncytial virus in high-risk adults and immunocompromised populations. Poster presented at the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) 2022 Conference; September 26, 2022. Belfast, United Kingdom.

Costello J, Colosia A, Kato K, Bertzos K, McQuarrie K. Systematic literature review of the signs and symptoms of respiratory syncytial virus in young children. Poster presented at the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) 2022 Conference; September 26, 2022. Belfast, United Kingdom.

Marvel J, Goransson O, Clark M, Romano (DeMuro) C, Olayinka-Amao O, Whalley D, Crawford R, Brindicci C, Garg K, Kordy K, Everhard F, Patalano F, Roesler Z, Landles R, Naujoks C, Gutzwiller FS. Interactive tablet application for self-report of asthma symptoms and impacts in young children. Poster presented at the ERS International Congress 2022; September 6, 2022. Barcelona, Spain. [abstract] Eur Respir J. 2022 Sep 4; 60(Suppl 66):2127. doi: 10.1183/13993003.congress-2022.2127

Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists. Int J Chron Obstruct Pulmon Dis. 2022 Aug 2;17:1715-33. doi: 10.2147/COPD.S363997

Rebordosa C, Farkas DK, Montonen J, Laugesen K, Voss F, Aguado J, Bothner U, Rothman KJ, Zint K, Mines DI, Ehrenstein V. Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists. Pharmacoepidemiol Drug Saf. 2022 Aug;31(8):827-39. doi: 10.1002/pds.5432

Saigi-Morgui N, Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud SZ, McMahon P, Perez-Gutthann S, Rivero-Ferrer E. Acute myocardial infarction, stroke, and MACE in COPD patients treated with aclidinium and other inhaled bronchodilators. Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.

Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2

Clark M, Romano C, Olayinka-Amao O, Whalley D, Crawford R, Pathak P, Brindicci C, Garg K, Kordy K, Everhard F, Patalano F, Roesler Z, Sutton T, Goransson O, Landles R, Naujoks C, Marvel J, Keininger DL. Development and content validation of a self-completed, electronic Pediatric Asthma Symptom Diary. J Patient Rep Outcomes. 2022 Mar 20;6(1):25. doi: 10.1186/s41687-022-00432-3

Simpson EL, de Bruin-Weller M, Bansal A, Chen Z, Nelson L, Whalley D, Prescilla R, Guillemin I, Delevry D. Definition of clinically meaningful within-patient changes in POEM and CDLQI in children 6 to 11 years of age with severe atopic dermatitis. Dermatol Ther. 2021 Aug;11(4):1415-22. doi: 10.1007/s13555-021-00543-7

Rebordosa C, Plana E, Rubino A, Aguado J, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. A cohort study to evaluate the risk of hospitalisation for congestive heart failure associated with the use of aclidinium and other chronic obstructive pulmonary disease medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. 2021 May 31;16:1461-75. doi: 10.2147/COPD.S301624

Davis A, Jiang J, Talbird S, Turpin RS, Mellott CE, Boules M, Wojtowicz AM, Fan T. Pharmacological costs for the treatment of eosinophilic esophagitis in the USA. Poster presented at the 2021 Virtual Digestive Disease Week (DDW) Conference; May 21, 2021. Previously presented at the 2021 AMCP Conference.

Oppenheimer J, Slade DJ, Hahn BA, Zografos L, Gilsenan A, Richardson D, McSorley D, Lima R, Molfino NA, Averell CM. Real-world evidence: patient views on asthma in respiratory specialist clinics in America. Ann Allergy Asthma Immunol. 2021 Apr;126(4):385-93. doi: 10.1016/j.anai.2020.12.015

Davis AE, Jiang J, Talbird SE, Turpin R, Mellott CE, Boules M, Wojtowicz AM, Fan T. Pharmacological costs for the treatment of eosinophilic esophagitis in the USA. Poster presented at the 2021 Virtual AMCP; April 2021.

Bell CF, Meyers J, Ajmera M. Incremental healthcare costs of Eosinophilic Granulomatosis with Polyangiitis (EGPA) compared to asthma: retrospective analysis of commercial claims data in the United States (US). Poster presented at the 2021 Virtual American College of Rheumatology (ACR) Convergence; November 6, 2021. [abstract] Arthritis Rheumatol. 2021; 73(Suppl 10).

Qin S, Nelson L, McLeod L, Ma J, López Sánchez B, Gamil M, Stevens M, Jane Scott J. Psychometric evaluation of the pediatric RSV severity and outcomes rating system version 7 (PRESORSv7.1, observer-reported and PRESORSv7 clinician- reported forms) scores in young children hospitalized with respiratory syncytial virus infection. Presented at the 2021 Virtual Visual ISOQOL 28th Annual Conference; October 12, 2021. [abstract] Qual Life Res. 2021; 30(Suppl 1):S16-7. doi: https://doi.org/10.1007/s11136-021-02976-1

Rebordosa C, Rubino A, Witzleb AJ, Olesen M, Plana E, Aguado J, Saigi N, Daoud SZ, Lei A, Perez-Gutthann S, Schink T, Kristiansen NS, Pottegard A, Rivero-Ferrer E. Characteristics of new users of aclidinium, aclidinium/formoterol, and other COPD medications in three European countries. Poster presented at the 2020 Virtual ERS International Congress; October 2020. [abstract] Eur Respir J. 2020 Oct 28; 56(Suppl 64):2071. doi: 10.1183/13993003.congress-2020.2072

Martinez D, Ziemiecki R, Aguado J, Plana E, Rebordosa C. Is chonic obstructive pulmonary disease reco(r)ded similarly in CPRD GOLD and Aurum? Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Rivero-Ferrer E, Witzleb AJ, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink T, Kristiansen NS, Pottegard A, Rebordosa C. Are aclidinium and aclidinium/formoterol used according to their approved indication in Europe? Results of a multicountry drug utilization postauthorization safety study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Davidson D, Stevenson M, Llonch MV, Hsieh A, Brown TM, Slota C, Fehnel S. Development of a novel patient-reported outcome measure symptoms and impacts of familial chylomicronemia syndrome. J Clin Lipidol. 2020 Jul;14(4):P571.

Crowe HM, Wise LA, Wesselink AK, Rothman KJ, Mikkelsen EM, Sorensen HT, Walkey AJ, Hatch EE. Association of asthma diagnosis and medication use with fecundability: a prospective cohort study. Clin Epidemiol. 2020 Jun 8;12:579-87. doi: 10.2147/CLEP.S245040

Molfino NA, Averell CM, Hahn BA, Zografos L, Gilsenan A, Richardson D, McSorley D, Slade DJ. Patients with uncontrolled asthma eligible for a biologic. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 20, 2020. Philadelphia, PA.

Molfino NA, Averell CM, Hahn B, Zografos L, Gilsenan A, Richardson D, McSorley D, Slade DJ. Real world evidence in asthma: pulmonary function and asthma control in respiratory specialty clinics in the US. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 20, 2020. Philadelphia, PA.

Averell CM, Hahn B, Zografos L, Gilsenan A, Richardson D, McSorley D, Molfino NA, Slade DJ. Assessment of asthma control in respiratory specialist offices in the US. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 17, 2020. Philadelphia, PA.

Rebordosa C, Houben E, Laugesen K, Bothner U, Montonen J, Aguado J, Overbeek JA, Ehrenstein V, Asmar J, Wallace L, Gilsenan AW. No evidence of off-label use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: a drug utilization study. Sci Rep. 2020 Jan 17;10(1):586. doi: 10.1038/s41598-019-57397-5

Zhang Y, Herring WL, Martin A, Gunsoy N, Zhang W. Development of a novel economic modeling approach for asthma. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Rebordosa C, Houben E, Laugesen K, Asmar J, Montonen JT, Aguado J, Overbeek J, Ehrenstein V, Wallace L, Gilsenan A. Utilization of olodaterol and indacaterol in Europe. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1128. doi: 10.1002/pds.4864

Plana E, Rivero-Ferrer E, Aguado J, Saigi-Morgui N, Nuevo J, Daoud SZ, Lei A, Perez-Gutthann S, Rebordosa C. Hospitalization for heart failure among patients using aclidinium bromide and other COPD medications: a post-authorisation safety study in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1153. doi: 10.1002/pds.4864

Saigi N, Rebordosa C, Bui C, Aguado J, Plana E, Nuevo J, Daoud SZ, Lei A, Perez-Gutthann S, Rivero-Ferrer E. A validation exercise: identifying hospitalizations for heart failure among patients with COPD in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):334. doi: 10.1002/pds.4864

Domdey A, Njue A, Nuabor W, Lyall M, Heyes A, Elliott L. Allergy immunotherapies for allergic rhinitis: systematic review and assessment of evolving quality. Eur Ann Allergy Clin Immunol. 2019 Jul;51(4):147-58. doi: 10.23822/EurAnnACI.1764-1489.100

Zullo R, Masaquel C, Taymour R, Stephenson B, Bell C. Systematic literature review of government-funded chronic disease programs in the United States. Poster presented at the 2019 Academy Health 19th Annual Research Meeting; June 2, 2019. Washington, DC.

Rebordosa C, Aguado J, Plana E, Thomas S, Frances A, Lei A, Garcia-Gil E, Nuevo J, Perez-Gutthann S, Castellsague J. Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom. Respir Med. 2019 Jun;152:37-43. doi: 10.1016/j.rmed.2019.04.018

Trantham L, Sikirica MV, Candrilli S, Benson VS, Mohan D, Neil D, Joshi AV. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis. J Med Econ. 2019 Apr;22(4):319-27. doi: 10.1080/13696998.2018.1563414.

Rebordosa C, Plana E, Aguado J, Thomas S, Garcia-Gil E, Perez-Gutthann S, Castellsague J. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):126-33. doi: 10.1002/pds.4448

Mansfield C, Sutphin J, Shriner K, Criner GJ, Celli BR. Patient preferences for endobronchial valve treatment of severe emphysema. Int J Chron Obstruct Pulmon Dis. 2019;6(1). doi: 10.15326/jcopdf.6.1.2018.0147

Lewis S, DeMuro C, Block SL, Senders S, Wisman P, Toback S, Chien JW, Williams V. Development of a novel observer-reported outcome measure for the assessment of Respiratory Syncytial Virus (RSV) infection symptoms in pediatric clinical trials. J Patient Rep Outcomes. 2018 Dec;2(9). doi: 10.1186/s41687-018-0034-9

Nagar SP, Fan Y, Meyers J, Tighe RM. Real-world treatment patterns of nintedanib among patients with idiopathic pulmonary fibrosis in the United States. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):S71.

Kelley K, Mordin M, Wronski S, Classi P. The relationship between non-invasive endpoints and long-term outcomes in pulmonary arterial hypertension: six-minute walk, functional class, and brain natriuretic peptide. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2018 Oct; 24(10-a):S61.

Aguado J, Plana E, Saigi N, Garcia-Gil E, Castellsague J, Perez-Gutthann S, Rebordosa C. The missing puff: results of multiple imputation of ppFEV1 in CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):211-2. doi: 10.1002/pds.4629

Plana E, Rebordosa C, Aguado J, Saigi N, Garcia-Gill E, Castellsague J, Perez-Gutthann S. To pile or not to pile: how to define episodes of use of COPD medications in the CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):123. doi: 10.1002/pds.4629

Rivero-Ferrer E, Castellsague J, Aguado J, Plana E, Saigi N, Garcia-Gil E, Perez-Gutthann S, Rebordosa C. Are you really dead? Validation of death and date of death in patients with COPD in the CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):122-3. doi: 10.1002/pds.4629